Modern approaches to the management of the social responsibility system in pharmacy

Research is devoted to the development of theoretical, methodological and scientific-practical principles of management of socially responsible activities of domestic pharmaceutical companies as a key condition for improving the quality, efficiency and accessibility of pharmaceutical supply, which is especially relevant in a global pandemic, closing state borders and domestic pharmaceutical companies with foreign partners. In addition, the introduction of approaches and tools of socially responsible management in the activities of domestic pharmaceutical companies will increase their investment attractiveness and improve their business reputation, which will have a positive impact on increasing their competitiveness in both domestic and foreign pharmaceutical markets. In the conditions of development of globalization and integration processes, formation of network economy and knowledge society, rapid expansion and complication of interrelations of national economies and people, growth of their interdependence the problem of socially responsible functioning of business, including based on the introduction of international standards of social responsibility (JI). The coronavirus pandemic (COVID-19) has also significantly changed attitudes toward company priorities around the world. The global pharmaceutical industry was one of the first to feel the effects of the closure of China's economy, which accounts for about 40% of world production of active pharmaceutical ingredients (APIs), and other raw material suppliers. The closure of borders and the long-term quarantine regime have posed significant threats not only to the supply chain for pharmaceutical manufacturers, but have also seriously affected the efficiency of pharmacy as a whole. There was a decrease in sales of prescription drugs (drugs), which complicates the withdrawal of new drugs and stimulates changes in the distribution system. The research activities of pharmaceutical companies (FCs) in non-COVID-19 areas have slowed significantly due to the pandemic. Most clinical trials have had to be suspended due to quarantine restrictions, which are slowing the launch of new drugs. Thus, the pandemic disrupted the normal functioning of all components of domestic pharmacy and exacerbated the problem of access to the population of quality pharmaceutical care. The current situation in domestic and international pharmacy should be a major impetus for a complete rethinking of the philosophy of FC, which in these difficult times must finally realize its own great JI, and begin to build more transparent, open, innovative and socially caring. Only the actions of the FC, as socially responsible organizations, will create hope for the survival not only of individual companies, but also of domestic pharmacy as a whole, and, accordingly, to preserve the health of the population of Ukraine.